Pulmonary hypertension drugs were never properly tested in heart failure.

Correspondence Financial/nonfi nancial disclosures: The authors have reported to CHEST the following confl icts of interest: Dr Lip has served as a consultant for Bayer; Astellas Pharma; Merck & Co; Sanofi ; Bristol-Myers Squibb/Pfi zer Inc; Daiichi Sankyo, Inc; BIOTRONIK; Portola Pharmaceuticals, Inc; and Boehringer-Ingelheim GmbH and has been on the speakers’ bureau of Bayer, Bristol-Myers Squibb/Pfi zer Inc, Boehringer-Ingelheim GmbH, and Sanofi -Aventis. Drs Apostolakis, Sullivan, and Olshansky have reported that no potential conflicts of interest exist with any companies/organiza tions whose products or services may be discussed in this article . Correspondence to: Gregory Y. H. Lip, MD, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Dudley Rd, Birmingham, B18 7QH, England; e-mail: g.y.h.lip@ bham.ac.uk © 2014 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details. DOI: 10.1378/chest.13-2775